Intrapleural Dornase and Tissue Plasminogen Activator in pediatric empyema (DTPA): a study protocol for a randomized controlled trial
This study protocol is for a superiority, placebo-controlled, parallel-design, multicenter randomized controlled trial. The participants are previously well children admitted to a children ’s hospital with a diagnosis of empyema requiring chest tube insertion and fibrinolytics administered intrapleurally. Children will be randomized after the treating physician has decided that pleural drainage is required but prior to chest tube insertion. After chest tube insertion, participants i n the treatment group will receive intrapleurally administered tissue plasminogen activator (tPA) 4 mg followed by dornase alfa 5&n...
Source: Trials - June 24, 2017 Category: Research Source Type: clinical trials

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions
Condition:   Loculated or Non-draining Malignant Pleural EffusionsIntervention:   Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)Sponsor:   Eastern Regional Medical CenterRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2014 Category: Research Source Type: clinical trials

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions
Condition:   Loculated or Non-draining Malignant Pleural EffusionsIntervention:   Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)Sponsor:   Eastern Regional Medical CenterNot yet recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2014 Category: Research Source Type: clinical trials

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions
Condition:   Loculated or Non-draining Malignant Pleural EffusionsIntervention:   Drug: Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)Sponsor:   Eastern Regional Medical CenterRecruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 8, 2014 Category: Research Source Type: clinical trials

Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis
Conditions:   Cystic Fibrosis;   RhinosinusitisInterventions:   Drug: Dornase alfa (Pulmozyme);   Drug: isotonic salineSponsor:   University of JenaCompleted - verified December 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 21, 2007 Category: Research Source Type: clinical trials

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)
Condition:   Otitis MediaIntervention:   Drug: dornase alfa (Pulmozyme®)Sponsors:   University of Colorado, Denver;   Genentech, Inc.Completed - verified March 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2007 Category: Research Source Type: clinical trials

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
Conditions:   Sinusitis;   Cystic FibrosisInterventions:   Drug: Pulmozyme (dornase alfa);   Drug: PlaceboSponsors:   University of Vermont;   Genentech, Inc.Completed - verified November 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 26, 2006 Category: Research Source Type: clinical trials